NorthSea Therapeutics announces positive Phase 2 topline data in first-ever randomized placebo-controlled study of an oral therapy in Intestinal Failure-Associated Liver Disease NorthSea Therapeutics announces late breaking oral presentation of Phase 2 topline data of Orziloben in Intestinal Failure-Associated Liver Disease at AASLD The Liver Meeting® 2026 onsemi to acquire Ferric, establishing leadership in power delivery for next-generation AI processors PlanetiQ expands GNSS-RO coverage with second satellite launch this month Promaxo lands $100M credit facility and Series C for MRI prostate platform Long Wall announces $75 million award from the Missile Defense Agency for Cyclops low-cost interceptor